行情

NTLA

NTLA

Intellia
NASDAQ

实时行情|Nasdaq Last Sale

13.30
-0.23
-1.70%
盘后: 13.30 0 0.00% 16:36 11/15 EST
开盘
13.69
昨收
13.53
最高
13.78
最低
13.15
成交量
41.75万
成交额
--
52周最高
19.00
52周最低
10.26
市值
6.50亿
市盈率(TTM)
-6.7736
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NTLA 新闻

  • 收盘:美股再创新高 道指首次跨越28000点里程碑
  • 新浪美股.37分钟前
  • 周五美油期货收高1.7% 布油上涨1.6%
  • 新浪美股.50分钟前
  • 分析师:某位投资大佬可能正在“嗅探”Netflix
  • 新浪财经.1小时前
  • FAA局长:737 MAX机型获复飞批准"不受时间表指引"
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
+1.49%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

NTLA 简况

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
展开

Webull提供Intellia Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。